诺和龙与二甲双胍联合治疗2型糖尿病的临床观察(2)
第1页 |
参见附件。
[参考文献]
[1] Rossetti L, Giaccari A, DeFronzo RA.Glucose toxicity[J]. Diabetes Care,1990,13(6): 610-630.
[2] Weyer C, Bogardus C, Mott DM, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus[J]. J Clin Invest,1999,104(6):787-794.
[3] David M,Nathan MD, John B,et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy[J]. Diabetes Care,2009,32(1):193-203.
[4] 过依.宁光.不同胰岛素促泌剂对胰岛β细胞分泌胰岛素的影响[J].中华内分泌代谢杂志,2005,21(3):206-210.
[5] Li CL,Pan CY,Lu JM,et al.Effect of metformin on patients with impaired glucose tolerance[J].Diabet Med,1999,16(6):477-481.
[6] Holman RR, Paul SK, Bethel MA,et al.10-year follow-up of in-tensive glucose control in type 2 diabetes[J].N Engl J Med, 2008,359:1577-1589.
[7] 石福彦.二甲双胍对心血管的保护作用[J].药品评价,2011,8(1):14-22.
[8] Raskin P.Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes[J].Diabetes Obes Metab,2008,10(12):1167-1177.
(收稿日期:2012-07-27)
您现在查看是摘要介绍页,详见PDF附件。